Farallon Capital Management’s Gilead Sciences GILD Stock Holding History

Farallon Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,920,000	Closed	-$207M	–	106
2018 Q2	$207M	Buy	2,920,000 +1,100,000	+60%	+$77.7M	1.28%	24
2018 Q1	$137M	Buy	+1,820,000	New	+$145M	0.95%	31
2017 Q4	–	Sell	-945,000	Closed	-$76.6M	–	85
2017 Q3	$76.6M	Buy	+945,000	New	+$72.3M	0.68%	38
2017 Q1	–	Sell	-135,000	Closed	-$9.67M	–	75
2016 Q4	$9.67M	Buy	+135,000	New	+$10M	0.11%	59
2015 Q3	–	Sell	-67,500	Closed	-$7.9M	–	89
2015 Q2	$7.9M	Buy	+67,500	New	+$7.38M	0.11%	72

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Farallon Capital Management's GILD Position: Q3 2018 in Review

Farallon Capital Management sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 2,920,000 shares — an estimated $207M sold.

Farallon Capital Management first reported a position in GILD in Q2 2015 and held it in 5 quarters. The position peaked at $207M in Q2 2018. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Farallon Capital Management reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Farallon Capital Management sold 2,920,000 Gilead Sciences shares in Q3 2018, an estimated $207M.
Farallon Capital Management first reported a position in Gilead Sciences in Q2 2015 and held it in 5 quarters.
Farallon Capital Management's Gilead Sciences position peaked at $207M in Q2 2018.
1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.